Drug Profile
Research programme: protein epitope mimetics cytokine inhibitors - AbbVie/Spexis
Latest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator Allergan; Polyphor
- Developer AbbVie; Spexis
- Class Cyclic peptides
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 06 Apr 2011 No development reported for Eye disorders in USA (Ophthalmic)
- 31 Oct 2008 Early research in Eye disorders in USA (Ophthalmic)